Clinical News

Select Clinical Trials Currently Enrolling Patients with Colorectal Cancer

April 2018, Vol 8, No 4 - Clinical Trials Tracker

The following clinical trials represent a selection of key studies that are currently recruiting patients with different types of colorectal cancer for inclusion in investigations of new therapies as well as new regimens of existing treatments for patients with colorectal cancer. Each description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncologists and other oncology practice providers direct eligible patients to an appropriate clinical trial. [ Read More ]

FDA Implements New Steps to Encourage Generic Drug Competition, Expand Patients’ Access to Inexpensive Medicines

Eileen Koutnik-Fotopoulos

April 2018, Vol 8, No 4 - Health Policy

In a January 3, 2018, statement from FDA Commissioner Scott Gottlieb, MD, the FDA announced new steps to promote generic drug competition as a way to expand potential access to inexpensive medicines, which would be especially helpful for patients with cancer. These new steps are a part of the FDA’s ongoing implementation of the Drug Competition Action Plan. [ Read More ]

Select Clinical Trials Currently Enrolling Patients with Lymphoma

March 2018, Vol 8, No 3 - Clinical Trials Tracker

The following clinical trials represent a selection of key studies that are currently recruiting patients with different types of lymphoma for inclusion in investigations of new therapies as well as new regimens of existing treatments for patients with lymphoma. Each description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncologists and other oncology practice providers direct eligible patients to an appropriate clinical trial. [ Read More ]

Imfinzi First Treatment Approved to Reduce Disease Progression in Unresectable Stage III NSCLC After Chemoradiation

March 2018, Vol 8, No 3 - FDA News

On February 16, 2018, the FDA approved an expanded indication for durvalumab (Imfinzi; AstraZeneca), a PD-L1 inhibitor, for the treatment of patients with unresectable stage III non–small-cell lung cancer (NSCLC) that did not progress after chemoradiation. Durvalumab received accelerated approval in 2017 for the treatment of certain patients with metastatic or locally advanced bladder cancer. [ Read More ]

Erleada First Therapy Approved for Patients with Nonmetastatic Castration-Resistant Prostate Cancer

March 2018, Vol 8, No 3 - FDA News

On February 14, 2018, apalu­tamide (Erleada; Janssen Pharmaceuticals), an androgen receptor inhibitor, received accelerated approval by the FDA for the treatment of patients with nonmetastatic, cas­tration-resistant prostate cancer (CRPC). Apalutamide is the first treatment approved by the FDA for patients with nonmetastatic CRPC, and was approved under the FDA priority review process. [ Read More ]

Lutathera First Radioactive Drug Approved for Adults with Gastroentero­pancreatic Neuroendocrine Tumors

March 2018, Vol 8, No 3 - FDA News

On January 26, 2018, the FDA approved lutetium Lu 177 dotatate (Lutathera; Advanced Accelerator Applications), a radioactive drug, for the treatment of adults with somato­statin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Lutetium Lu 177 dotatate was approved under the FDA’s priority review process, and was designated as an orphan drug. [ Read More ]

Gilotrif Receives New Indication as First-Line Treatment for Metastatic NSCLC with Nonresistant EGFR Mutations

March 2018, Vol 8, No 3 - FDA News

On January 12, 2018, afatinib (Gilotrif; Boehringer Ingelheim) received FDA approval as first-line treatment for patients with metastatic non–small-cell lung cancer (NSCLC) associated with nonresistant EGFR mutations as identified via an FDA-approved test. Afatinib received orphan drug status for this indication, and was approved under the FDA priority review process. [ Read More ]

The Butterfly Effect: Improving the Chemotherapy Visit Experience

Gail Thompson

February 2018, Vol 8, No 2 - Practice Operations

The “butterfly effect” in chaos theory refers to a phenomenon in which a small, localized change in a complex system can have large effects elsewhere. Cody Boyd, BSHA, RT (R)(T), University of Texas Health Science Center at Tyler Cancer Treatment and Prevention Center, shared the experience of such a change at the ACCC National Oncology Conference in October 2017 in Nashville. [ Read More ]